Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INNV OTCMKTS:IPCIF NASDAQ:SLRX NASDAQ:TNXP OTCMKTS:WCUI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINNVInnovAge$4.14-1.4%$3.92$2.60▼$6.69$567.05M0.5151,154 shs128,742 shsIPCIFIntellipharmaceutics International$0.00$0.00▼$0.15$4.96M1.5312,042 shsN/ASLRXSalarius Pharmaceuticals$0.75-4.0%$0.84$0.45▼$7.20$1.66M0.441.56 million shs187,676 shsTNXPTonix Pharmaceuticals$40.87-3.5%$32.58$6.76▼$130.00$311.65M2.05969,642 shs612,208 shsWCUIWellness Center Usa$0.00-80.0%$0.00$0.00▼$0.00$10K4.8950 shs1,000 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINNVInnovAge-1.43%-6.55%+8.66%+46.81%-17.37%IPCIFIntellipharmaceutics International0.00%0.00%0.00%0.00%0.00%SLRXSalarius Pharmaceuticals-3.98%-15.96%-1.58%+19.45%-72.73%TNXPTonix Pharmaceuticals-3.52%+15.13%+8.38%+142.12%-34.08%WCUIWellness Center Usa0.00%-81.82%-81.82%0.00%-80.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINNVInnovAge0.9967 of 5 stars1.82.00.00.02.21.70.6IPCIFIntellipharmaceutics InternationalN/AN/AN/AN/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals0.4412 of 5 stars0.02.00.00.03.30.00.6TNXPTonix Pharmaceuticals2.6603 of 5 stars3.52.00.00.01.73.30.6WCUIWellness Center UsaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINNVInnovAge 1.50Reduce$5.0020.77% UpsideIPCIFIntellipharmaceutics International 0.00N/AN/AN/ASLRXSalarius Pharmaceuticals 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 3.00Buy$585.001,331.37% UpsideWCUIWellness Center Usa 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TNXP, IPCIF, WCUI, SLRX, and INNV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINNVInnovAge$763.85M0.73N/AN/A$2.04 per share2.03IPCIFIntellipharmaceutics International$660K0.00N/AN/A($0.32) per share0.00SLRXSalarius PharmaceuticalsN/AN/AN/AN/A$0.95 per shareN/ATNXPTonix Pharmaceuticals$10.09M29.81N/AN/A$31.82 per share1.28WCUIWellness Center Usa$660K0.02N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINNVInnovAge-$21.34M-$0.23N/A69.00N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)IPCIFIntellipharmaceutics International-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals-$5.58M-$4.82N/A∞N/AN/A-324.13%-174.40%8/8/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)WCUIWellness Center Usa-$750KN/A0.00∞N/AN/AN/AN/AN/ALatest TNXP, IPCIF, WCUI, SLRX, and INNV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SLRXSalarius Pharmaceuticals-$2.40-$1.03+$1.37-$1.03N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 million5/6/2025Q3 2025INNVInnovAge-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINNVInnovAgeN/AN/AN/AN/AN/AIPCIFIntellipharmaceutics InternationalN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/AWCUIWellness Center UsaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINNVInnovAge0.040.780.78IPCIFIntellipharmaceutics InternationalN/AN/AN/ASLRXSalarius PharmaceuticalsN/A1.011.01TNXPTonix PharmaceuticalsN/A12.3111.64WCUIWellness Center UsaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINNVInnovAge12.26%IPCIFIntellipharmaceutics InternationalN/ASLRXSalarius Pharmaceuticals11.88%TNXPTonix Pharmaceuticals82.26%WCUIWellness Center Usa0.01%Insider OwnershipCompanyInsider OwnershipINNVInnovAge1.40%IPCIFIntellipharmaceutics International1.76%SLRXSalarius Pharmaceuticals1.20%TNXPTonix Pharmaceuticals0.03%WCUIWellness Center Usa15.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINNVInnovAge2,350135.01 million133.12 millionOptionableIPCIFIntellipharmaceutics International1033.09 million32.51 millionNot OptionableSLRXSalarius Pharmaceuticals202.13 million2.10 millionNot OptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableWCUIWellness Center Usa8143.19 million120.71 millionNot OptionableTNXP, IPCIF, WCUI, SLRX, and INNV HeadlinesRecent News About These CompaniesLamar Mental Wellness Center in Augusta aids mental health needsJuly 11 at 1:32 PM | msn.comFlagler Schools cut ribbon on new Wellness CenterJuly 9 at 2:48 AM | observerlocalnews.comOWest Monroe Honors Local Businesses with “Yard of the Month” Award for Outstanding Beautification to The Wellness CenterJuly 5, 2025 | msn.comAvas Wellness Center and Spa to Anchor a Growing Wellness-Driven Ecosystem in AlibaugJuly 2, 2025 | devdiscourse.comDErie Cancer Wellness Center Free Outdoor Summer Wellness Series July 10July 1, 2025 | erienewsnow.comE‘Shocked’: North Portland Wellness Center scorched by 3-alarm fireJune 10, 2025 | msn.comWildcat Wellness Center set to close in July for summer breakJune 4, 2025 | msn.comSenior wellness expo draws increased attendance at YMCA Wellness CenterMay 21, 2025 | msn.comLumiClinics Behavioral Wellness Center Revolutionizes Mental Health Care with Integrated ApproachMay 17, 2025 | news.marketersmedia.comNCancer Wellness Center of NEPA holds Annual WalkMay 12, 2025 | timesleader.comTCancer Wellness Center gears up for major walk fundraiserMay 7, 2025 | msn.comWellness Center attendance upApril 16, 2025 | sdsucollegian.comSMCCTC Plans New Health and Wellness CenterApril 11, 2025 | businessjournaldaily.comBRegional Wellness Center project planning on pause amid funding uncertaintyApril 11, 2025 | duboiscountyfreepress.comDVictorville’s Wellness Center receives major funding from San Bernardino CountyApril 11, 2025 | msn.comUSD To Host Wellness Center Natatorium Grand Opening And Ribbon CuttingApril 11, 2025 | plaintalk.netPSam Raan Spa & Wellness Center Wins a 2025 Global Recognition Award for Exceptional Service ExcellenceMarch 31, 2025 | news.marketersmedia.comNAgeWell Services continuing its mission despite Wellness Center and Cafe closureMarch 28, 2025 | msn.comMultimillion dollar transformation set for Norfolk Fitness and Wellness CenterMarch 28, 2025 | wtkr.comWAgeWell Services will close Wellness Center, Driftwood Café amid budget concernsMarch 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP, IPCIF, WCUI, SLRX, and INNV Company DescriptionsInnovAge NASDAQ:INNV$4.14 -0.06 (-1.43%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.11 -0.03 (-0.72%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.Intellipharmaceutics International OTCMKTS:IPCIFIntellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.Salarius Pharmaceuticals NASDAQ:SLRX$0.75 -0.03 (-3.98%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.70 -0.04 (-5.88%) As of 07/11/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Tonix Pharmaceuticals NASDAQ:TNXP$40.87 -1.49 (-3.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$40.66 -0.21 (-0.52%) As of 07/11/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.Wellness Center Usa OTCMKTS:WCUI$0.0001 0.00 (-80.00%) As of 07/9/2025 09:30 AM EasternWellness Center USA, Inc. engages in the healthcare and medical business in the United States and internationally. The company operates through Medical Devices; and Authentication and Encryption Products and Services segments. It is primarily involved in the marketing and distribution of online sports and nutrition supplements. The company also designs, develops, manufactures, markets, and distributes targeted ultraviolet phototherapy devices that include Psoria-Light, which is used in targeted PUVA photochemistry and UVB phototherapy for the treatment of skin conditions, such as psoriasis, vitiligo, atopic dermatitis, seborrheic dermatitis, and leukoderma. In addition, it offers intelligent microparticles, which provide technologies within the security and supply chain management vertical sectors; and ActiveDuty, a data intelligence service comprising proprietary, unprecedented, and actionable technology, which include a suite of analytical tools, such as artificial intelligence and social psychology for industries, companies, and agencies. The company was incorporated in 2010 and is based in Tucson, Arizona. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
